These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 17602016)
1. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Kreyenbuhl J; Marcus SC; West JC; Wilk J; Olfson M Psychiatr Serv; 2007 Jul; 58(7):983-90. PubMed ID: 17602016 [TBL] [Abstract][Full Text] [Related]
2. [Psychiatrists' decision making and monitoring of antipsychotic prescription for elderly schizophrenia patients]. Jalenques I; Ortega V; Legrand G; Auclair C Encephale; 2016 Apr; 42(2):124-9. PubMed ID: 26796558 [TBL] [Abstract][Full Text] [Related]
3. Psychiatrists' awareness of partial- and non-adherence to antipsychotic medication in schizophrenia: results from the Australian ADHES survey. Kulkarni J; Reeve-Parker K Australas Psychiatry; 2015 Jun; 23(3):258-64. PubMed ID: 25783668 [TBL] [Abstract][Full Text] [Related]
4. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. Loosbrock DL; Zhao Z; Johnstone BM; Morris LS J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539 [TBL] [Abstract][Full Text] [Related]
5. National trends in psychotropic medication polypharmacy in office-based psychiatry. Mojtabai R; Olfson M Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220 [TBL] [Abstract][Full Text] [Related]
6. Substance abuse and the management of medication nonadherence in schizophrenia. Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865 [TBL] [Abstract][Full Text] [Related]
7. The effectiveness of guideline implementation strategies on improving antipsychotic medication management for schizophrenia. Owen RR; Hudson T; Thrush C; Thapa P; Armitage T; Landes RD Med Care; 2008 Jul; 46(7):686-91. PubMed ID: 18580387 [TBL] [Abstract][Full Text] [Related]
8. Psychiatric opinion and antipsychotic selection in the management of schizophrenia. Arbuckle MR; Gameroff MJ; Marcus SC; West JC; Wilk J; Olfson M Psychiatr Serv; 2008 May; 59(5):561-5. PubMed ID: 18451017 [TBL] [Abstract][Full Text] [Related]
9. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Leslie DL; Rosenheck RA Am J Psychiatry; 2002 Sep; 159(9):1534-40. PubMed ID: 12202274 [TBL] [Abstract][Full Text] [Related]
11. Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria: Characteristics associated with high reported antipsychotic polypharmacy. James BO; Omoaregba JO; Raji SO; Imishue OE; Okonoda KM; Nyamali YI; Famuyiwa PA; Correll CU Psychiatry Res; 2017 Feb; 248():134-139. PubMed ID: 28063386 [TBL] [Abstract][Full Text] [Related]
12. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial. Constantine RJ; Andel R; McPherson M; Tandon R Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142 [TBL] [Abstract][Full Text] [Related]
13. Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. Correll CU; Brevig T; Brain C BMC Psychiatry; 2019 Nov; 19(1):362. PubMed ID: 31727015 [TBL] [Abstract][Full Text] [Related]
14. Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. Sernyak MJ; Leslie D; Rosenheck R Am J Psychiatry; 2003 Feb; 160(2):310-5. PubMed ID: 12562578 [TBL] [Abstract][Full Text] [Related]
15. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]. Bret P; Bret MC; Queuille E Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381 [TBL] [Abstract][Full Text] [Related]
16. Are patients with schizophrenia under-treated with second-generation antipsychotics? A pilot study of the prescription practices of German psychiatrists. Hamann J; Pfeiffer H; Leucht S; Kissling W Pharmacopsychiatry; 2003 Nov; 36(6):309-12. PubMed ID: 14663656 [TBL] [Abstract][Full Text] [Related]
17. Psychiatrists' self-reported adherence to evidence-based prescribing practices in the treatment of schizophrenia. Young GJ; Mohr DC; Meterko M; Seibert MN; McGlynn G Psychiatr Serv; 2006 Jan; 57(1):130-2. PubMed ID: 16399975 [TBL] [Abstract][Full Text] [Related]
18. Psychiatrists' psychotropic drug prescription preferences for themselves or their family members. Latas M; Stojkovic T; Ralic T; Milovanovic S; Jasovic-Gasic M Psychiatr Danub; 2012 Jun; 24(2):182-7. PubMed ID: 22706417 [TBL] [Abstract][Full Text] [Related]
19. Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Olfson M; Marcus SC; Wilk J; West JC Psychiatr Serv; 2006 Feb; 57(2):205-11. PubMed ID: 16452697 [TBL] [Abstract][Full Text] [Related]
20. Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective. Altamura AC; Armadoros D; Jaeger M; Kernish R; Locklear J; Volz HP Curr Med Res Opin; 2008 Aug; 24(8):2271-82. PubMed ID: 18588748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]